Long-Term Non-Interventional Latanoprost Study (LYNX)

Viatris

Status: Completed

Conditions: Glaucoma; Ocular Hypertension

Treatments: Other: No intervention other than routine medical care

Study type: Observational

Funder types: Industry

Identifiers

NCT01265719

A6111143

LYNX (Other Identifier)

PFI-LAT-2009-01 (Other Identifier)

Details and patient eligibility

About

This is a non-interventional, prospective, longitudinal cohort study. A total of 150 pediatric subjects with glaucoma or elevated intraocular pressure, including 75 latanoprost-treated subjects and 75 non-topical prostaglandin analogue treated subjects, will be enrolled from ophthalmic hospital clinics and academic ophthalmic centers. As a non-interventional study, the study subjects' continued use of latanoprost and assessments of ocular events will be obtained through the routine medical follow-up with treating ophthalmologists or other designated members of the medical care team.

Full description

At least 40 subjects in each of the following age groups: 1-<5 years and 5-<18 years. No minimum required numbers in the <1 year age group.

Enrollment: 175 patients

Sex: All

Ages: 1 day to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female <18 years of age (neonates must be at least 36 weeks gestational age).
• Diagnosis of pediatric glaucoma or elevated intraocular pressure.
• Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.

For treated subjects only:

• Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.

For untreated subjects only:

• Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
• No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period.

Exclusion criteria

• Unable/unwilling to comply with protocol.
• Pregnant or nursing females at baseline.
• For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).

Trial design

175 participants in 2 patient groups

Latanoprost-treatment group

Treatment:

Other: No intervention other than routine medical care

Other: No intervention other than routine medical care

Non-topical prostaglandin analogue treatment group

Treatment:

Other: No intervention other than routine medical care

Other: No intervention other than routine medical care